IQVIA (IQV)

• Market cap: $35.8B
• 1 day: 3.00%
• 5 days: -1.05%
• 1 month: 1.49%
• 3 months: -18.52%
• 6 months: -7.90%
• Year to date: -14.38%
• 1 year: -12.32%
• 5 years: 26.50%
• 10 years: 228.29%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Employees: 88,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

45% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 77

23% more repeat investments, than reductions

Existing positions increased: 429 | Existing positions reduced: 350

8% more funds holding in top 10

Funds holding in top 10: 12 [Q2] → 13 (+1) [Q3]

7% more capital invested

Capital invested by funds: $34.2B [Q2] → $36.7B (+$2.43B) [Q3]

3% more funds holding

Funds holding: 1,002 [Q2] → 1,037 (+35) [Q3]

3.73% less ownership

Funds ownership: 88.92% [Q2] → 85.19% (-3.73%) [Q3]

11% less call options, than puts

Call options by funds: $208M | Put options by funds: $234M

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $212 7% upside
• Avg. target: $254 29% upside
• High target: $276 40% upside

15 analyst ratings

• positive: 14 93%
• neutral: 1 7%
• negative: 0 0%

Stephens & Co. Jeff Garro 43% 1-year accuracy 3 / 7 met price target	27% upside $250	Overweight Initiated	20 Dec 2024
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target	19% upside $235	Buy Maintained	13 Dec 2024
Truist Securities Jailendra Singh 14% 1-year accuracy 5 / 35 met price target	32% upside $261	Buy Maintained	12 Dec 2024
RBC Capital Sean Dodge 50% 1-year accuracy 21 / 42 met price target	37% upside $270	Outperform Reiterated	11 Dec 2024
Baird Eric Coldwell 32% 1-year accuracy 11 / 34 met price target	7% upside $212	Neutral Maintained	11 Dec 2024